Steris Plc (ireland) · NYSE:STE
Steris Plc (ireland) — STERIS — Merger or Acquisition (January 2021)
16 slides from Steris Plc (ireland)'s merger presentation, Jan 12, 2021
Slide 1: STERIS to Acquire Cantel Medical
STERIS to Acquire CantelMedical January 12, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION No Offer or Solicitation This announcement is f
Slide 3: Forward Looking Statements (continued)
Forward Looking Statements CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION (CONTINUED) •operating costs, Customer loss and business disruption (including, without limitation, difficulties in maintaining relationshipswith employees, Customers, clients or suppliers) being greater than expec
Slide 4: Forward Looking Statements: Additional Information and Where to Find It
Forward Looking Statements Additional Information and Where to Find It In connection with the proposed transaction, STERIS will file a registration statement on Form S-4 with the SEC. INVESTORS AND SECURITY HOLDERS ARE ENCOURAGED TO READ THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FI
Slide 5: Non-GAAP Financial Measures
5 Non-GAAP Financial Measures Adjusted net income, adjusted EBIT, free cash flow and constant currency organic revenue are non-GAAP measures that may be used from time to time and should not be considered replacements for GAAP results. Non-GAAP financial measures are presented in this release with t
Slide 6: Today's Hosts
Today’s Hosts Walt Rosebrough STERIS President & CEO Michael J. Tokich STERIS SVP, Chief Financial Officer Daniel A. Carestio STERIS Chief Operating Officer George Fotiades CantelMedical CEO6
Slide 7: STERIS Mission, Vision & Values
STERIS Mission, Vision & Values MISSION WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. VISION We strive to be a GREAT COMPANY. We provide world-class products and services for our Customers,
Slide 8: About STERIS
About STERIS ~25% of revenue OUS FY20 BALANCED REVENUE STREAM 13,000 Associates Worldwide Over 3,000 Customer facing sales and service professionals $3.0 BILLION Revenue In FY20 75% Recurring 25% Capital S&P 500 Russell 10008
Slide 9: Serving Growth Areas Within Healthcare
Serving Growth Areas Within Healthcare 65% 21% 14% HealthcareA comprehensive offering for healthcare providers worldwide, focused on the sterile processing department and procedural centers such as operating rooms. Our solutions for sterile processing range from infection prevention consumables, cap
Slide 10: About Cantel Medical
About CantelMedical Cantelis focused on providing solutions for complex reprocessing workflows to prevent healthcare related infections A leader in Infection Prevention for endoscopy and dental providers offering a Complete Circle of Protection (“CCOP”) Leading Global Brands COVID-19 reinforces the
Slide 11: Snapshot of Cantel
Snapshot of Cantel Use Point-of-use Cleaning Transport Disinfection Inspection/Pack & Prep Sterilization Sterile Storage Transport •Publicly traded on NYSE under ticker “CMD” •Strategically focused on infection prevention for GI centers, dental offices, ambulatory surgical centers,and dialysis servi
Slide 12: History of Cantel Performance
History of CantelPerformance Fiscal Year Ending July 31 $0 $200 $400 $600 $800 $1,000 $1,200 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Net Reported Sales Adjusted EBITDAS 10 Yr. CAGR ~14% ~14% Organic Growth 4% 12% 4% 6% 11% 9% 13% 11% 8% 4% (6%) Further information can be found in the
Slide 13: Cantel Strategic Rationale
CantelStrategic Rationale Below are the key highlights of the strategic rationale for the transaction: •The product offering, global reach and Customer set are naturally complementary. -Cantel’slargest business, its Medical portfolio, will add increased presence in Endoscopy, with a full suite of le
Slide 14: Cantel Transaction Details
CantelTransaction Details KEY TERMS FISCAL 2021 IMPACT SYNERGIES OTHER CONSIDERATIONS •100% of Cantelto be acquired from its current shareholders (NYSE: CMD) •$4.6 billion in total enterprise value -combination of stock and debt •Implied Cantelownership of ~15% •Anticipate closing by the end of STER
Slide 15: STERIS and Cantel are Well Positioned for Continued Growth
STERIS and Cantelare well Positioned for Continued Growth •We are a leading global provider of products and services that meet the needs of growth areas within Healthcare: procedures, devices, vaccines, biologics and dental. •We offer comprehensive sterilization and disinfection solutions for a broa
Slide 16: STERIS plc Investor Relations Contact
STERIS plc Investor Relations Contact: Julie Winter julie_winter@steris.com